A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials (Q37524053)

20 August 2017

A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials (English)

1 reference

20 August 2017

1

H P Selker

1 reference

20 August 2017

Ralph B. D'Agostino Sr.

10

object named as

R B D'Agostino

1 reference

20 August 2017

K A Oye

2

1 reference

20 August 2017

H-G Eichler

3

1 reference

20 August 2017

N L Stockbridge

4

1 reference

20 August 2017

C R Mehta

5

1 reference

20 August 2017

K I Kaitin

6

1 reference

20 August 2017

N E McElwee

7

1 reference

20 August 2017

P K Honig

8

1 reference

20 August 2017

J K Erban

9

1 reference

20 August 2017

language of work or name

English

0 references

publication date

23 September 2013

1 reference

Clinical Pharmacology & Therapeutics

20 August 2017

1 reference

20 August 2017

95

1 reference

20 August 2017

2

1 reference

20 August 2017

147-153

1 reference

Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Random treatment assignment using mathematical equipoise for comparative effectiveness trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Optimizing trial design: sequential, adaptive, and enrichment strategies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Adaptive licensing: taking the next step in the evolution of drug approval

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction. A multicenter, randomized, controlled, clinical effectiveness trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

The future of drug development: advancing clinical trial design.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904553

HER2 status and benefit from adjuvant trastuzumab in breast cancer

2 September 2018

1 reference

12 December 2020

Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument

1 reference

12 December 2020

Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty for acute myocardial infarction

1 reference

12 December 2020

Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction

1 reference

12 December 2020

Legal foundations of adaptive licensing

1 reference

12 December 2020

A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

1 reference

12 December 2020

Identifiers

DOI

10.1038/CLPT.2013.177

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

24060819

1 reference